HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

Verification of the effectiveness of fucosylated haptoglobin as a pancreatic cancer marker in clinical diagnosis

This item is licensed under: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

Files in This Item:
Pancreatology_19_569.pdf871.06 kBPDFView/Open
Please use this identifier to cite or link to this item:

Title: Verification of the effectiveness of fucosylated haptoglobin as a pancreatic cancer marker in clinical diagnosis
Authors: Kuwatani, Masaki Browse this author →KAKEN DB
Kawakami, Hiroshi Browse this author →KAKEN DB
Kubota, Yoshimasa Browse this author
Kawakubo, Kazumichi Browse this author
Ito, Yoichi M. Browse this author →KAKEN DB
Togo, Shinji Browse this author
Ikeda, Takaaki Browse this author
Kusama, Ken Browse this author
Kobayashi, Yuka Browse this author
Murata, Teizo Browse this author
Sakamoto, Naoya Browse this author →KAKEN DB
Keywords: CA19-9
Fucosylated haptoglobin
Pancreatic cancer
Issue Date: Jun-2019
Publisher: Elsevier
Journal Title: Pancreatology
Volume: 19
Issue: 4
Start Page: 569
End Page: 577
Publisher DOI: 10.1016/j.pan.2019.04.007
PMID: 31031206
Abstract: Background: Fucosylated haptoglobin detected by Pholiota squarrosa lectin (PhoSL) that had specificity for fucose alpha 1-6 was reported as an effective biomarker for several gastrointestinal diseases. The aim of this study was to verify Fucosylated haptoglobin detected by Pholiota squarrosa lectin (PhoSL-HP) as a pancreatic cancer (PC) marker using a new method of PhoSL-ELISA. Methods: PhoSL-HP in sera from 98 PC patients and 158 non-PC samples including 32 intraductal papillary mucinous neoplasm (IPMN) patients, 21 chronic pancreatitis (CP) patients and 105 non-pancreatic disease controls (NPDC) were measured. We compared sensitivities, specificities and areas under the curves (AUC) of PhoSL-HP, CA19-9 and CEA as single markers. We also evaluated PhoSL-HP as combination marker by comparing AUC of CA19-9 combined with PhoSL-HP or CEA. Results: The sensitivities of PhoSL-HP, CA19-9 and CEA for PC were 58%, 76% and 42%, respectively. Although the specificity of PhoSL-HP for NPDC was inferior to both of CA19-9 and CEA, that for pancreatic diseases was higher than both of CA19-9 and CEA. Combined CA19-9 with PhoSL-HP, the AUC was significantly higher at 0.880 than single use of CA19-9 at 0.825 in case of distinguishing PC from other pancreatic diseases. In contrast, the AUC of CA19-9 was not elevated significantly when combined with CEA. Conclusion: PhoSL-HP would be a useful marker for PC and have sufficient complementarity for CA19-9. (C) 2019 Published by Elsevier B.V. on behalf of IAP and EPC.
Rights: © 2019. This manuscript version is made available under the CC-BY-NC-ND 4.0 license
Type: article (author version)
Appears in Collections:北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 桒谷 将城

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 - Hokkaido University